As we recently discussed, the Federal Trade Commission (“FTC”) sent warning letters to certain drug manufacturers regarding their purportedly improper listing of device patents in the Food and Drug Administration’s (“FDA”)...more
3/18/2024
/ Antitrust Violations ,
Biotechnology ,
Enforcement Actions ,
Federal Trade Commission (FTC) ,
Food & Drug Regulations ,
Food and Drug Administration (FDA) ,
Life Sciences ,
Manufacturers ,
Medical Devices ,
Orange Book ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Unfair Competition ,
Warning Letters
On November 7, 2016, the U.S. Supreme Court declined to review an appeal from a Third Circuit decision finding that a settlement between GlaxoSmithKline (GSK) and Teva Pharmaceutical Industries Ltd. (Teva) involving the...more
11/15/2016
/ Anti-Competitive ,
Antitrust Violations ,
Appeals ,
Denial of Certiorari ,
FTC v Actavis ,
Generic Drugs ,
GlaxoSmithKline ,
No-AG Agreement ,
Pay-For-Delay ,
Popular ,
Product Exclusivity ,
Reverse Payment Settlement Agreements ,
Rule-of-Reason Analysis ,
SCOTUS ,
Solicitor General ,
Teva Pharmaceuticals